| Abstract | Essential arterial hypertension often predisposes patients to prothrombotic state and increased risk of vascular and organ complications. Vital role in regulation of hemostatic processes is played by genetic factors, renin-angiotensin system and disorders of lipid metabolism. Prime genetic factors involved in the process are 4G/5G polymorphism of promoter region coding tissue plasminogen activator inhibitor-1 (PAI-1) and I/D polymorphism for angiotensin converting enzyme (ACE) gene. The aim of work was the evaluation of alterations within fibrinolysis system (estimation of t-PA and PAI-1 levels), fibrinogen concentration (Fb) and ACE activity with regard to co-existent dyslipidemia and features of left ventricle hypertrophy (LVH). Moreover the analysis of influence of 4G/5G PAI and I/D ACE gene polymorphism on intensification of aforementioned alterations among hypertensive patients was performed. Research was carried out in 170 subjects under 40 years old, in two study groups, HT-- hypertensive group--125 patients with previously untreated hypertension without clinical features of ischaemic heart disease and NT--45 normotensive, healthy subjects. HT group has been further divided into four subgroups: DLP (dyslipidemic, n = 51), NLP (normolipidemic n = 74), LVH+ (with features of left ventricle hypertrophy, n = 35), LVH (-) (without features of left ventricle hypertrophy, n = 90). In a whole HT group significantly higher levels of PAI-1, t-PA and Fb were noted in comparison to NT group, considerably more pronounced within DLP rather than NLP subgroups. Moreover, pronounced increase in ACE activity was recorded in DLP and LVH+ subgroups. It has been proved that 4G/4G homozygous subjects of 4G/5G PAI-1 gene polymorphism from HT group tend to present higher levels of PAI-1 and t-PA if contrasted to 4G/4G genotype of NT group, with more distinct effect within DLP subgroup. Carriers of D allele (genotypes I/D, D/D) of I/D ACE gene polymorphism from HT group characterise with significantly higher activity of ACE in contrast to I/I genotype of HT group, with particularly marked effect in DLP and LVH+ subgroups. Basing on above mentioned results it may be concluded that essential hypertension (especially if complicated with dyslipidemia) impairs fibrinolysis, what might be related to renin-angiotensin system activation in lipid metabolism disorders. Deletion alleles of 4G/5G polymorphism (4G allele) and I/D polymorphism (D allele) in patients with hypertension independently modify fibrinolysis towards prothrombotic state with more distinct effect in dyslipidemia. Increased activity of ACE in D allele carriers may predispose to left ventricle hypertrophy. |
| Authors | Maria Jastrzebska, Krystyna Widecka, Andrzej Ciechanowicz, Iwona Goracy, Teresa Wesołowska, Barbara Torbus-Lisiecka, Anna Foltyńska-Nowakowska, Marek Naruszewicz
(Affiliation: Katedra Biochemii Klinicznej i Diagnostyki Laboratoryjnej Pomorskiej AM w Szczecinie. mariajas at sci.pam.szczecin.pl)
|
| Journal | Polskie archiwum medycyny wewnȩtrznej
(Pol Arch Med Wewn)
Vol. 113
Issue 1
Pg. 7-20
(Jan 2005)
ISSN: 0032-3772 [Print] Poland |
| Vernacular Title | Polimorfizmy 4G/5G genu inhibitora aktywatora plazminogenu (PAI-1) oraz I/D genu enzymu konwertujacego angiotensyne I (ACE) a aktywność fibrynolityczna u chorych z samoistnym nadciśnieniem tetniczym i dyslipidemia. |
| PMID | 16130596
(Publication Type: English Abstract, Journal Article, Research Support, Non-U.S. Gov't)
|
| Chemical References |
- Plasminogen Activator Inhibitor 1
- Fibrinogen
- Peptidyl-Dipeptidase A
- Tissue Plasminogen Activator
|
| Topics |
- Adult
- Analysis of Variance
- Case-Control Studies
- Female
- Fibrinogen
(analysis, genetics)
- Fibrinolysis
(genetics)
- Humans
- Hyperlipidemias
(blood, genetics)
- Hypertension
(blood, genetics)
- Hypertrophy, Left Ventricular
(genetics)
- Male
- Peptidyl-Dipeptidase A
(blood, genetics, metabolism)
- Plasminogen Activator Inhibitor 1
(blood, genetics, metabolism)
- Poland
- Polymerase Chain Reaction
(methods)
- Polymorphism, Genetic
- Risk Assessment
- Risk Factors
- Tissue Plasminogen Activator
(blood)
|